Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astria Therapeutics Inc ATXS

Healthcare Biotechnology
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a... see more

Recent & Breaking News (NDAQ:ATXS)

Catabasis Pharmaceuticals to Participate in the Citi 10th Annual Biotech Conference and Present at the NewsMakers in the Biotech Industry Conference

Business Wire September 2, 2015

Catabasis Pharmaceuticals Reports Second Quarter 2015 Financial Results and Recent Corporate Highlights

Business Wire August 13, 2015

Catabasis Pharmaceuticals Announces Positive Top-line Phase 1 Data for Hypercholesterolemia Product Candidate CAT-2054

Business Wire August 13, 2015

Catabasis Pharmaceuticals to Present at the American Chemical Society National Conference

Business Wire August 11, 2015

Catabasis Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference

Business Wire August 4, 2015

Catabasis Pharmaceuticals Will Present the CAT-2000 Program of SREBP Modulators for Hyperlipidemias at the Kern Lipid Conference

Business Wire July 28, 2015

Catabasis Pharmaceuticals and UT Southwestern Medical Center Enter into a Sponsored Research Agreement for CAT-2000 Series in Serious Lipid Disorders

Business Wire July 27, 2015

Catabasis Pharmaceuticals Receives FDA Fast Track Designation for CAT-1004 for the Treatment of Duchenne Muscular Dystrophy

Business Wire July 6, 2015

Catabasis Pharmaceuticals Announces Closing of Initial Public Offering

Business Wire June 30, 2015

Catabasis Pharmaceuticals Announces Pricing of Initial Public Offering

Business Wire June 25, 2015